Возможности использования дорназы альфа (Пульмозим) в детской пульмонологии

1. Таточенко В.К. (ред.). Практическая пульмонология детского возраста. М; 2001.

2. Picot R., Das /., Reid L. Pus desoxyribonucleic acid and sputum viscosity. Thorax 1978; 33: 235-242.

3. Christopher F., Chase D., Steink K., Milne R. rhDNase therapy for the treatment of cystic fibrosis patients with mild to moderate lung disease. J. Clin. Pharmacol. Ther 1999; 24: 415-426.

4. Stutts M.J., Canessa C.M., Olsen J.C. et al. CFTR as a cAMP-dependent regulator of sodium channels. Science 1995; 269: 847-850.

5. Капранов Н.И., Волков И.К., Зоирова Р. Исследование вязкости мокроты для оценки эффективности муколитической терапии детей больных муковисцидозом. Вопр. охр. мат. 1985; 2: 35-39.

6. Капранов Н.И., Гембицкая Т.Е., Симонова О.И. и др. Опыт длительного применения нового муколитического препарата "Пульмозим" у больных муковисцидозом. Тер. арх. 2001; 1: 55-58.

7. Potter J.L., Spector S ., Mattheus L .W ., Lemni J. Studies on pulmonary secretions. 3. The nucleic acids in whole pulmonary secretions from patients with cystic fibrosis, bronchoectasis, and laryngectomy. Am. Rev. Respir. Dis. 1969; 99: 909-916.

8. Shah P.L., Conway S., Scott S.F. et al. A case-controlled study with dornase alfa to evaluate impact on disease progression over a 4 year period. Respiration 2001; 6 8 : 160-164.

9. Hodson M.E., McKenzie S., Harms H.K. et al. Dornase alfa in the treatment of cystic fibrosis in Europe: a report from the Epidemiologic Registry of Cystic Fibrosis. Pediatr Pulmonol. 2003; 36 (5): 427-432.

10. Hodson M.E., Shah P.L. Dnase trials in cystic fibrosis. Eur. Respir. J. 1995; 8 : 1786-1791.

11. Fuchs H.J., Borowitz D.S., Christiansen D.H. et al. Effect of aerosolized recombinant human Dnase on exacerbations of respiratory symptom s and on pulmonary functions in patients with cystic fibrosis: the Pulmozyme study group. N. Engl. J. Med. 1994; 331: 637-642.

12. Волков И.K., Давыдова И.В., Куличихин В.Г., Симонова О.И. и др. Эффективность дорназы альфа (Пульмозим) у детей с хроническими заболеваниями легких. Пульмонология 2003; 3: 79-82.

13. Puchelle E., Zahm J.M., de Bentzmann S. et al. Effects of rhDNase on purulent airway secretions in chronic bronchitis. Eur. Respir. J. 1996; 9 (4): 765-769.

14. Berge M., Brinkhorst G., Kroon A.A., Jongste J.C. DNase treatment in primary ciliary dyskinesia-assessm ent by nocturnal pulse oximetry. Pediatr. Pulmonol. 1999; 27: 59 -61 .

15. Yoo Y., Koh Y. Y. Current treatment for primary ciliary dyskinesia conditions. Expert. Opin. Pharmacother. 2004; 5 (2): 369-377.

16. Merkus P.J., de Hoog M., van Gent R., de Jongste J.C. DNase treatment for atelectasis in infants with severe respiratory syncytial virus bronchiolitis. Eur. Respir. J. 2001; 18 (4):

17. N asr S.Z., Strouse P.J., Soskolne E. et al. Efficacy of recombinant hum an deoxyribonuclease I in the hospital management of respiratory syncytial virus bronchiolitis. Chest 2001; 120: 203-208.

18. Spencer H. Pathology of the lung. Oxford: Pergamon Press; 1985. 131-165.

19. Kupeli S., Teksam O., Dogru D., Yurdakok M. Use of recombinant hum an DNase in a premature infant with recurrent atelectasis. Pediatr. Int. 2003; 45: 584-586.

20. El Hassan N.O., Chess P.R., Huysm an M. et al. Rescue use of DNase in critical lung atelectasis and mucus retention in premature neonates. Pediatrics 2001; 108: 468-471.

21. Durward A., Forte V., Shemie S.D. Resolution of mucus plugging and atelectasis after intratracheal rhDNase therapy in a mechanically ventilated child with refractory status asthmaticus. Crit. Care Med. 2000; 28 (2): 560-562.

22. Manna S.S., Shaw J., Tibby S.M., Durward A. Treatment of plastic bronchitis in acute chest syndrome of sickle cell disease with intratracheal rhDNase. Arch. Dis. Childh. 2003; 8 8: 626-627.

23. Bush A. Bronchoscopy in pediatric intensive care. Pediatr. Respir. Rev. 2003; 4 (1): 67-73.

24. Slattery D.M., Waltz D.A., Denham B. et al. Bronchoscopically administered recombinant hum an D Nase for lobar atelectasis in cystic fibrosis. Pediatr. Pulmonol. 2001; 1 (5): 383-388.

25. Simpson G., Roomes D., Reeves B. Successful treatment of empyema thoracis with human recombinant deoxyribonuclease. Thorax 2003; 58: 363-366.

26. Christopher F., Chase D., Steink K., M ilne R. rhDNase therapy for the treatment of cystic fibrosis patients with mild to moderate lung disease. J. Clin. Pharmacol. Ther. 1999; 24: 415-426.

27. Conway S.P. Evidence-based medicine in cystic fibrosis: how should practice change? Pediatr. Pulmonol. 2002; 34: 242-247.

28. Quan J.M., Tiddens H.A., Sy J.P. et al. A two-year randomized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities. J. Pediatr. 2001; 139 ( 6 ): 813-820.

29. Sun F., Tai S., Lim T. et al. Additive effect of dornase alfa and Nacystelyn on transportability and viscoelasticity of cystic fibrosis sputum. Can. Respir. J. 2002; 9 (6): 401-406.

30. Robinson P.J. Dornase alfa in early cystic fibrosis lung disease. Pediatr. Pulmonol. 2002; 34 (3): 237-241.

31. Ramsey B.W., Dorkin H.L. Practical applications of Pulmozyme. Pediatr. Pulmonol. 1994; 17: 404-408.

32. Капранов H.H., Воронкова A .10., Шабалова Л.A. и др. Клиническое значение рекомбинантной человеческой ДНКазы (Пульмозим) в комплексной терапии больных муковисцидозом. Рос. педиатр, журн. 2001; 3: 26-31.